4d Pharma PLC Appointment of independent Non-Executive Directors (4321M)
January 08 2019 - 1:00AM
UK Regulatory
TIDMDDDD
RNS Number : 4321M
4d Pharma PLC
08 January 2019
4D pharma plc
(the "Company" or "4D")
Appointment of independent Non-Executive Directors
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the
development of Live Biotherapeutics, today announces the
appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher,
MD, as independent Non-Executive Directors with immediate
effect.
Ed Baracchini, PhD, was previously the Chief Business Officer at
Xencor Inc. where he led strategic alliances and licensing. During
his time at Xencor he negotiated license agreements with Novartis
($2.6B: immune-oncology bispecific antibodies), Novo Nordisk
($600M: drug discovery collaboration), Amgen ($500M: option and
development agreement autoimmune disease antibody) among numerous
others. Prior to that he served as SVP Business Development for
Metabasis Therapeutics.
Professor Dr. med. Axel Glasmacher was until recently Senior
Vice President and Head of the Global Clinical Research and
Development Hematology-Oncology at Celgene, where he has worked in
various roles for more than ten years. His work at Celgene led to
the approvals of Revlimid(R), Idhifa(R), and Vidaza(R)
(haematological cancers). He also worked on the PD-L1 inhibitor
durvalumab. Prior to Celgene, Professor Glasmacher worked within
the fields of hematology-oncology at the University Hospital in
Bonn.
Duncan Peyton, 4D's Chief Executive Officer, commented: "We
welcome Axel and Ed to our Board with great pleasure. Their
collective experience will strengthen our commercial and
therapeutic focus, as 4D accelerates development of its extensive
pipeline in cancer and other immunological diseases."
The following information is disclosed in accordance with Rule
17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.
Edgardo (Ed) Baracchini Jr., 59, has no interest in shares in 4D
pharma plc and has the following current and previous company
directorships and partnerships:
Current Company Directorships and Partnerships:
None
Company Directorships and Partnerships held in last 5 years:
INmune Bio, Inc.
Axel Gaston Glasmacher, 58, has no interest in shares in 4D
pharma plc and has the following current and previous company
directorships and partnerships:
Current Company Directorships and Partnerships:
AG Life Science Consulting GmbH & Co. KG - finalisation of
formal incorporation pending
Glasmacher Verwaltungs-GmbH - finalisation of formal
incorporation pending
Company Directorships and Partnerships held in last 5 years:
None
Save for the disclosures above, there are no further disclosures
to be made in accordance with Rule 17 and Schedule 2 paragraph (g)
of the AIM Rules for Companies.
For further information please contact:
4D
Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130
Fay Weston, Head of Investor Relations + 44 (0)7990 381713
Zeus Capital Limited - Nomad and Joint Broker +44 (0) 161 831 1512
Dan Bate / Jordan Warburton
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson / Phil Walker
About 4D
Founded in February 2014, 4D is a world leader in the
development of live biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as bacteria, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform that rationally identifies novel bacteria that
have a precise and evolved therapeutic effect. All of 4D's live
biotherapeutic products are orally delivered single strains of
bacteria that are naturally found in the healthy human gut. 4D has
a phase II study in Irritable Bowel Syndrome running and has a
pipeline of 13 pre-clinical programmes, covering disease areas such
as cancer, poorly controlled asthma, autoimmune and CNS disease.
The Company plans to commence three additional clinical studies in
2019.
For more information, refer to https://www.4dpharmaplc.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASSFFWWFUSEIF
(END) Dow Jones Newswires
January 08, 2019 02:00 ET (07:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024
